Thymosin Beta-4 Reference

Plain English

What it is

Thymosin beta-4 is a natural peptide, a small protein the body makes that helps repair tissue after injury and damage. It is the full-length parent of a popular research-chemical fragment known as TB-500. It is not an approved medicine, so it is treated as a research chemical rather than a treatment.

What people use it for

People in the peptide community look to thymosin beta-4 for recovery themes, such as healing the heart, nerves, and other tissues, often after an injury or surgery. Most of what is known comes from animal studies, with only a handful of early human trials, so a lot of the interest carries over from talk about its TB-500 fragment.

What the science shows

It has reached human trials, including a placebo-controlled heart-attack study and eye-healing studies, but results have not been strong enough to earn approval. In the heart-attack trial the overall difference versus placebo was not significant, and researchers said more rigorous studies are needed. Animal heart research has also raised cautions about how it works and noted its potential still needs full exploration.

The catch

Thymosin beta-4 is not FDA-approved and is not a proven treatment for heart disease or wound healing. The FDA has flagged its TB-500 fragment as a compounding safety concern, and anti-doping authorities ban this peptide family in sport, where athletes have been given multi-year sanctions for it. The research-grade material may also differ from the exact form used in the published studies.

Reference summary

The literature is a mix of animal regeneration studies and newer translational cardiac work, including a small placebo-controlled STEMI trial. TB-500 marketing claims still extrapolate from full-length Tbeta4 rather than a settled human TB-500 evidence base.

Regulatory and posture

Categories

Recovery

Aliases

Thymosin beta-4, TB4, TB4 full peptide

Evidence posture

translational - Human translational data are narrow and do not establish a general recovery protocol.

Regulatory status

No FDA-approved injectable thymosin beta-4 drug label. Human translational work exists, but product identity differs from commercial TB-500 fragments and no routine approved protocol exists.

Content review status

research reference

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• Injection-site rotation overview - Public overview of the Pro site-rotation planner.